Get the Stockscreener App
66.30
7.31%
-5.23
After Hours:
66.30
Ani Pharmaceuticals Inc stock is traded at $66.30, with a volume of 756.04K.
It is down -7.31% in the last 24 hours and up +0.44% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$71.53
Open:
$76.01
24h Volume:
756.04K
Relative Volume:
2.12
Market Cap:
$1.57B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
80.85
EPS:
0.82
Net Cash Flow:
$100.45M
1W Performance:
-9.12%
1M Performance:
+0.44%
6M Performance:
+7.91%
1Y Performance:
+0.64%
1-Day Range:
$65.96
$77.00
1-Week Range:
$65.96
$77.00
52-Week Range:
$52.50
$77.00
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
66.30 | 1.57B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
ANI Pharmaceuticals raises 2025 revenue guidance to $768M-$793M with 25%-29% growth - MSN
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ANI Pharmaceuticals beats Q1 2025 forecasts, stock surges - Investing.com India
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insigh - GuruFocus
ANI Pharmaceuticals Reports Record Q1 2025 Results - TipRanks
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact - AOL.com
ANI: Q1 Earnings Snapshot - The Washington Post
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Transcript : ANI Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
ANI Pharmaceuticals, Inc. Q1 Profit Decreases, But Beats Estimates - Nasdaq
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance - The Manila Times
ANI Pharmaceuticals (NASDAQ:ANIP) Reports Strong Q1, Full-Year Outlook Slightly Exceeds Expectations - FinancialContent
(ANIP) ANI Pharmaceuticals Expects Fiscal Year 2025 Revenue Range $768M$793M - marketscreener.com
ANI Pharmaceuticals, Inc. Raises Earnings Guidance for the Year 2025 - marketscreener.com
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? - MSN
ANI Pharmaceuticals Files Proxy for 2025 Meeting - TipRanks
Earnings To Watch: ANI Pharmaceuticals (ANIP) Reports Q1 Results Tomorrow - FinancialContent
ANI Pharmaceuticals: A Short-Term Buying Opportunity (NASDAQ:ANIP) - Seeking Alpha
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance - ADVFN
ANI Pharmaceuticals (ANIP) Highlights Promising Cortrophin Gel P - GuruFocus
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
ANI Pharmaceuticals Announces Presentation of Preclinical - GlobeNewswire
Breakthrough: ANI's Cortrophin Gel Achieves Dose-Dependent Success in Autoimmune Eye Disease Trial - Stock Titan
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Scotiabank Announces Redemption of US $1,250 million 4.900% Fixed Rate Resetting Perpetual Subordinated Additional Tier 1 Capital Notes - The Globe and Mail
The 4.0% return this week takes ANI Pharmaceuticals' (NASDAQ:ANIP) shareholders three-year gains to 135% - simplywall.st
Zacks.com featured highlights include Heritage Insurance, Marex, Kingstone, ANI Pharmaceuticals and HCI - Yahoo Finance
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Zacks.com featured highlights include ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon - Yahoo Finance
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue - TradingView
Truist raises ANI Pharmaceuticals target to $65, maintains hold By Investing.com - Investing.com India
Truist Lifts Price Target on ANI Pharmaceuticals to $65 From $62, Keeps Hold Rating - marketscreener.com
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
ANI Pharmaceuticals (ANIP): Buy, Sell, Or Hold Post Q4 Earnings? - Barchart.com
Ani Pharmaceuticals Sr. VP sells $27,583 in stock By Investing.com - Investing.com Canada
StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell - MarketBeat
Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
ANI Pharmaceuticals (ANIP) Set for Potential Earnings Beat - GuruFocus
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - GlobeNewswire
ANI Pharmaceuticals Reveals Q1 2025 Earnings Date: Key Executive Insights Coming May 9 - Stock Titan
Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE - Yahoo Finance
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO - TradingView
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):